ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Response of COVID-19 vaccination in multiple sclerosis patients following disease-modifying therapies: A meta-analysis

Wu, Xi; Wang, Lu; Shen, Lu; Tang, Kefu*上海交通大学
EBioMedicine2022-7DOI: 10.1016/j.ebiom.2022.104102
26被引6阅读
引用收藏
分享

摘要

Background COVID-19 vaccination is recommended for patients with multiple sclerosis (pwMS), while disease -modifying therapies (DMTs) may influence the efficacy of SARS-CoV-2 vaccines in this population. Thus, we con-ducted a meta-analysis to evaluate the impact of DMTs on immune response to COVID-19 vaccines in pwMS. @@@ Methods Literature search from December 1, 2019 to March 31, 2022 was performed in PubMed, MedRxiv, Embase and Cochrane Library. The risk of impaired response to vaccination in pwMS receiving DMTs was estimated in odds ratios (ORs) using random-effects method. @@@ Findings A total of 48 studies comprising 6860 pwMS were included. Overall, pwMS with anti-CD20 (OR=0.02, 95% CI: 0.01-0.03) and sphingosine-1-phosphate receptor modulator (S1PRM) (OR=0.03, 95% CI: 0.01-0.06) treat-ments had attenuated serologic response after full vaccination compared with those without DMTs. Additionally, pwMS vaccinated within six months since last anti-CD20 therapy were at significantly higher risk of blunted response compared with those receiving anti-CD20 therapy more than six months prior to vaccination (P = 0.001). We found no significant associations between other treatments (including IFN-b, GA, DMF, TERI, NTZ, CLAD, and ALE) and humoral response to SARS-CoV-2 vaccines in pwMS. As for T-cell response, no significant difference was found between pwMS on anti-CD20 and those without DMTs after vaccination, while S1PRM was marginally associated with impaired cellular response (P = 0.03). @@@ Interpretation Our findings suggested that routine serological monitoring may be required for pwMS on anti-CD20 and S1PRMs after SARS-CoV-2 vaccination and highlighted the benefits of a booster dose. The effect of cellular response and optimal interval from last anti-CD20 treatment to vaccination should be further addressed. @@@ Funding This study was supported by Natural Science Foundation of Shanghai (21ZR1433000).

学科与关键词

关键词
COVID-19 vaccinesMultiple sclerosisDisease-modifying therapiesImmune responseMeta-analysis
相关
加载中…
  • Impaired serological response to COVID-19 vaccination following anticancer therapy: A systematic review and meta-analysis
    Tang, Kefu*; Wei, Zhiying; Wu, Xi*Journal of Medical Virology, 2022, 94(10): 4860-4868.被引 10
  • Immune response to vaccination against SARS-CoV-2 in hematopoietic stem cell transplantation and CAR T-cell therapy recipients
    Wu, Xi; Wang, Lu; Shen, Lu; He, Lin; Tang, Kefu*Journal of Hematology & Oncology, 2022, 15(1): 81.被引 25
  • Meta-analysis of immunologic response after COVID-19 mRNA vaccination in solid organ transplant recipients
    Tang, Kefu*; Wu, Xi; Luo, Ying; Wei, Zhiying; Feng, Liyun; Wu, LeiJournal of Infection, 2022, 84(5): E73-E75.被引 10
查看全部 →

发表信息

论文状态
公开发表
期刊
EBioMedicine
发表日期
2022-07
卷期
第 81 卷
页码
104102
DOI
10.1016/j.ebiom.2022.104102
期刊等级
1区
成果收录
SCIE
资助标注
Natural Science Foundation of Shanghai [21ZR1433000]

作者

  • W

    Wu, Xi (第一作者)

    shanghai jiao tong univ · x

  • W

    Wang, Lu

    shanghai jiao tong univ · x

查看全部 4 位作者收起作者
  • S

    Shen, Lu

    shanghai jiao tong univ · x

  • T

    Tang, Kefu (通讯)

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417